Evaluación de tres dosis de potasio en la producción de lechuga (Lactuca sativa L. var. Crispa) bajo el sistema hidropónico recirculante NTF bajo invernadero

Three doses of potassium were evaluated in the production of lettuce (Lactuca sativa L. var. Crispa), under the recirculable NFT hydroponic system in the greenhouse of the Department of Horticulture of the ESPOCH. A completely randomized block design was used with three treatments and three replications. The doses evaluated were: low dose (LD) with 224,33 ppm, medium dose (MD) with 470,00 ppm, and high dose (HD) with 716,67 ppm. Evaluated parameters were: potassium content in leaves and root, fresh weights of the aerial part and root, yield per net plot and hectare. The economic analysis was carried out according to the relation benefit/cost. The best results for most of the parameters evaluated were obtained with the low dose (LD), obtaining fresh weights of the aerial part and root of 193,01 and 36,65 g respectively. It has a yield per net plot of 2,04 kilograms and per hectare of 15338,75 kilograms, and the highest cost benefit with 4,63 dollars equivalent to 362,75%. On the other hand, the highest content of potassium in leaves and root up to 40 days after transplant (DAT) was obtained with the medium dose (MD) with 5,13 and 6,00% of total potassium, respectively. In all treatments, maintaining turgor in the plants throughout the cycle is very important. From the agronomic and economic point of view, the use a nutritive solution containing 224,33 ppm of potassium was recommended

Improved catalytic activity of ruthenium–arene complexes in the reduction of NAD+

A series of neutral Ru-II half-sandwich complexes of the type [(eta(6)-arene)Ru(N,N')Cl] where the arene is para-cymene (p-cym), hexamethylbenzene (hmb), biphenyl (bip), or benzene (bn) and N,N' is N-(2-aminoethyl) -4-(trifluoromethyl)benzenesulfonamide (TfEn), N-(2-aminoethyl)-4-toluenesulfonamide (TsEn), or N-(2-aminoethyl)-methylenesulfonamide (MsEn) were synthesized and characterized. X-ray crystal structures of [(p-cym)Ru(MsEn)Cl] (1), [(hmb)Ru(TsEn)Cl] (5), [(hmb)Ru(TfEn)Cl] (6), [(bip)Ru(MsEn)Cl] (7), and [(bip)Ru(TsEn)Cl] (8) have been determined. The complexes can regioselectively catalyze the transfer hydrogenation of NAD(+) to give 1,4-NADH in the presence of formate. The turnover frequencies (TOF) when the arene is varied decrease in the order bn > bip > p-cym > hmb for complexes with the same N,N' chelating ligand. The TOF decreased with variation in the N,N' chelating ligand in the order TfEn > TsEn > MsEn for a given arene. [(bn)Ru(TfEn)Cl] (12) was the most active, with a TOP of 10.4 h(-1). The effects of NAD(+) and formate concentration on the reaction rates were determined for [(p-cym)Ru(TsEn)Cl] (2). Isotope studies implicated the formation of [(arene)Ru(N,N')(H)] as the rate-limiting step. The coordination of formate and subsequent CO2 elimination to generate the hydride were modeled computationally by density functional theory (DFT). CO2 elimination occurs via a two-step process with the coordinated formate first twisting to present its hydrogen toward the metal center. The computed barriers for CO2 release for arene = benzene follow the order MsEn > TsEn > TfEn, and for the Ms En system the barrier followed bn < hmb, both consistent with the observed rates. The effect of methanol on transfer hydrogenation rates in aqueous solution was investigated. A study of pH dependence of the reaction in D2O gave the optimum pH* as 7.2 with a TOF of 1.58 h(-1) for 2. The series of compounds reported here show an improvement in the catalytic activity by an order of magnitude compared to the ethylenediamine analogues

Un examen actualizado de la percepción de las barreras para la implementación de la farmacogenómica y la utilidad de los pares fármaco/gen en América Latina y el Caribe

La farmacogenómica (PGx) se considera un campo emergente en los países en desarrollo. La investigación sobre PGx en la región de América Latina y el Caribe (ALC) sigue siendo escasa, con información limitada en algunas poblaciones. Por lo tanto, las extrapolaciones son complicadas, especialmente en poblaciones mixtas. En este trabajo, revisamos y analizamos el conocimiento farmacogenómico entre la comunidad científica y clínica de ALC y examinamos las barreras para la aplicación clínica. Realizamos una búsqueda de publicaciones y ensayos clínicos en este campo en todo el mundo y evaluamos la contribución de ALC. A continuación, realizamos una encuesta regional estructurada que evaluó una lista de 14 barreras potenciales para la aplicación clínica de biomarcadores en función de su importancia. Además, se analizó una lista emparejada de 54 genes/fármacos para determinar una asociación entre los biomarcadores y la respuesta a la medicina genómica. Esta encuesta se comparó con una encuesta anterior realizada en 2014 para evaluar el progreso en la región. Los resultados de la búsqueda indicaron que los países de América Latina y el Caribe han contribuido con el 3,44% del total de publicaciones y el 2,45% de los ensayos clínicos relacionados con PGx en todo el mundo hasta el momento. Un total de 106 profesionales de 17 países respondieron a la encuesta. Se identificaron seis grandes grupos de obstáculos. A pesar de los continuos esfuerzos de la región en la última década, la principal barrera para la implementación de PGx en ALC sigue siendo la misma, la "necesidad de directrices, procesos y protocolos para la aplicación clínica de la farmacogenética/farmacogenómica". Las cuestiones de coste-eficacia se consideran factores críticos en la región. Los puntos relacionados con la reticencia de los clínicos son actualmente menos relevantes. Según los resultados de la encuesta, los pares gen/fármaco mejor clasificados (96%-99%) y percibidos como importantes fueron CYP2D6/tamoxifeno, CYP3A5/tacrolimus, CYP2D6/opioides, DPYD/fluoropirimidinas, TMPT/tiopurinas, CYP2D6/antidepresivos tricíclicos, CYP2C19/antidepresivos tricíclicos, NUDT15/tiopurinas, CYP2B6/efavirenz y CYP2C19/clopidogrel. En conclusión, aunque la contribución global de los países de ALC sigue siendo baja en el campo del PGx, se ha observado una mejora relevante en la región. La percepción de la utilidad de las pruebas PGx en la comunidad biomédica ha cambiado drásticamente, aumentando la concienciación entre los médicos, lo que sugiere un futuro prometedor en las aplicaciones clínicas de PGx en ALC.Pharmacogenomics (PGx) is considered an emergent field in developing countries. Research on PGx in the Latin American and the Caribbean (LAC) region remains scarce, with limited information in some populations. Thus, extrapolations are complicated, especially in mixed populations. In this paper, we reviewed and analyzed pharmacogenomic knowledge among the LAC scientific and clinical community and examined barriers to clinical application. We performed a search for publications and clinical trials in the field worldwide and evaluated the contribution of LAC. Next, we conducted a regional structured survey that evaluated a list of 14 potential barriers to the clinical implementation of biomarkers based on their importance. In addition, a paired list of 54 genes/drugs was analyzed to determine an association between biomarkers and response to genomic medicine. This survey was compared to a previous survey performed in 2014 to assess progress in the region. The search results indicated that Latin American and Caribbean countries have contributed 3.44% of the total publications and 2.45% of the PGx-related clinical trials worldwide thus far. A total of 106 professionals from 17 countries answered the survey. Six major groups of barriers were identified. Despite the region’s continuous efforts in the last decade, the primary barrier to PGx implementation in LAC remains the same, the “need for guidelines, processes, and protocols for the clinical application of pharmacogenetics/pharmacogenomics”. Cost-effectiveness issues are considered critical factors in the region. Items related to the reluctance of clinicians are currently less relevant. Based on the survey results, the highest ranked (96%–99%) gene/drug pairs perceived as important were CYP2D6/tamoxifen, CYP3A5/tacrolimus, CYP2D6/opioids, DPYD/fluoropyrimidines, TMPT/thiopurines, CYP2D6/tricyclic antidepressants, CYP2C19/tricyclic antidepressants, NUDT15/thiopurines, CYP2B6/efavirenz, and CYP2C19/clopidogrel. In conclusion, although the global contribution of LAC countries remains low in the PGx field, a relevant improvement has been observed in the region. The perception of the usefulness of PGx tests in biomedical community has drastically changed, raising awareness among physicians, which suggests a promising future in the clinical applications of PGx in LAC

Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation : Data From ROCKET AF

M. Kaste on työryhmän ROCKET AF Steering Comm jäsen.Background-Atrial fibrillation is associated with higher mortality. Identification of causes of death and contemporary risk factors for all-cause mortality may guide interventions. Methods and Results-In the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) study, patients with nonvalvular atrial fibrillation were randomized to rivaroxaban or dose-adjusted warfarin. Cox proportional hazards regression with backward elimination identified factors at randomization that were independently associated with all-cause mortality in the 14 171 participants in the intention-to-treat population. The median age was 73 years, and the mean CHADS(2) score was 3.5. Over 1.9 years of median follow-up, 1214 (8.6%) patients died. Kaplan-Meier mortality rates were 4.2% at 1 year and 8.9% at 2 years. The majority of classified deaths (1081) were cardiovascular (72%), whereas only 6% were nonhemorrhagic stroke or systemic embolism. No significant difference in all-cause mortality was observed between the rivaroxaban and warfarin arms (P=0.15). Heart failure (hazard ratio 1.51, 95% CI 1.33-1.70, P= 75 years (hazard ratio 1.69, 95% CI 1.51-1.90, P Conclusions-In a large population of patients anticoagulated for nonvalvular atrial fibrillation, approximate to 7 in 10 deaths were cardiovascular, whereasPeer reviewe

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

BACKGROUND: The cholesteryl ester transfer protein inhibitor evacetrapib substantially raises the high-density lipoprotein (HDL) cholesterol level, reduces the low-density lipoprotein (LDL) cholesterol level, and enhances cellular cholesterol efflux capacity. We sought to determine the effect of evacetrapib on major adverse cardiovascular outcomes in patients with high-risk vascular disease. METHODS: In a multicenter, randomized, double-blind, placebo-controlled phase 3 trial, we enrolled 12,092 patients who had at least one of the following conditions: an acute coronary syndrome within the previous 30 to 365 days, cerebrovascular atherosclerotic disease, peripheral vascular arterial disease, or diabetes mellitus with coronary artery disease. Patients were randomly assigned to receive either evacetrapib at a dose of 130 mg or matching placebo, administered daily, in addition to standard medical therapy. The primary efficacy end point was the first occurrence of any component of the composite of death from cardiovascular causes, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina. RESULTS: At 3 months, a 31.1% decrease in the mean LDL cholesterol level was observed with evacetrapib versus a 6.0% increase with placebo, and a 133.2% increase in the mean HDL cholesterol level was seen with evacetrapib versus a 1.6% increase with placebo. After 1363 of the planned 1670 primary end-point events had occurred, the data and safety monitoring board recommended that the trial be terminated early because of a lack of efficacy. After a median of 26 months of evacetrapib or placebo, a primary end-point event occurred in 12.9% of the patients in the evacetrapib group and in 12.8% of those in the placebo group (hazard ratio, 1.01; 95% confidence interval, 0.91 to 1.11; P=0.91). CONCLUSIONS: Although the cholesteryl ester transfer protein inhibitor evacetrapib had favorable effects on established lipid biomarkers, treatment with evacetrapib did not result in a lower rate of cardiovascular events than placebo among patients with high-risk vascular disease. (Funded by Eli Lilly; ACCELERATE ClinicalTrials.gov number, NCT01687998 .)

Lichenomphalia altoandina, a new species of Hygrophoraceae from the Chilean Altiplano

Lichenomphalia is a lichenized agaric genus characterized by its omphalinoid basidiomes.Lichenomphalia species are associated with unicellular green algae in the genus Coccomyxa andare mainly distributed in polar and alpine habitats. The aim of this work is to describe L.altoandina, a new species from northern Chile that grows among cushion plants over 3000 mabove sea level in the Andes Mountains. The species is remarkable for living in highly salineenvironments, in some cases virtually on salt crusts. Lichenomphalia altoandina differs from otherknown species and particularly from L. aurantiaca, the most morphologically similar species, in itssmooth and broader stipe and its slightly larger spores. Lichenomphalia altoandina is alsomorphologicaly and ecologically more similar to the core Lichenomphalia clade. Our phylogeneticstudy based on nuclear rDNA ITS and partial 28S sequences shows that L. altoandina belongs tothe Protolichenomphalia clade and is sister to an unknown lineage, L. aff. umbellifera, from NewZealand.Fil: Sandoval Leiva, P.. Biota Gestión y Consultorías Ambientales Ltda; ChileFil: Niveiro, Nicolás. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Nordeste. Instituto de Botánica del Nordeste. Universidad Nacional del Nordeste. Facultad de Ciencias Agrarias. Instituto de Botánica del Nordeste; ArgentinaFil: Urbina Casanova, R.. Universidad de Chile; ChileFil: Scherson, R.. Universidad de Chile; Chil

Vibrisseaceous fungi from the southern hemisphere, including Chlorovibrissea chilensis (Helotiales, incertaesedis) sp. nov.

The discovery of Chlorovibrissea chilensis sp. nov. expands the geographic distribution of Chlorovibrissea from Australasia to include South America. C. chilensis, phylogenetically distinct from other species in the genus, is characterized morphologically by its ascoma with emerald green stalk and pale orange brown head, budding paraphyses and 5-6-septate ascospores. Based on the phylogenetic analysis, the Australasian species Vibrissea albofusca is recombined in Chlorovibrissea, despite it lacking the distinctive green pigmentation of other species in this genus. In addition, the genus Vibrissea in a strict genetic sense is confirmed from the Southern Hemisphere for the first time; Vibrissea truncorum is reported from Chile and V. flavovirens from New Zealand.Fil: Sandoval Leiva, Pablo. Biota Gestión y Consultorías Ambientales Ltda; ChileFil: Carmaran, Cecilia Cristina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Micología y Botánica. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Micología y Botánica; ArgentinaFil: Park, D.. Crown Research Institutes. Landcare Research; Nueva ZelandaFil: Romero, Andrea Irene. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Micología y Botánica. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Micología y Botánica; ArgentinaFil: Johnston, P. R.. Crown Research Institutes. Landcare Research; Nueva Zeland

How to know the fungi: combining field inventories and DNA‐barcoding to document fungal diversity

The fungi kingdom is among the most diverse eukaryotic lineages on Earth with estimates of several million extant species (O´Brien et al., 2005; Blackwell, 2011; Taylor et al., 2014). Fungi play critical roles in carbon and nutrient cycling of terrestrial and aquatic ecosystems, and they are important pathogens and mutualists (Read & Perez-Moreno, 2003; Taylor et al., 2012; Grossart et al., 2016). More than 80% of plant species form symbioses with fungi and these symbioses have been crucial to the colonization of terrestrial ecosystems (Field et al., 2015a; Selosse et al., 2015). Despite their impacts on primary ecosystem functions, assessments of fungal biodiversity estimate that only c. 10% of fungal species have been described (Bass & Richards, 2011; Hibbett et al., 2011).Fil: Truong, Camille. University of Florida; Estados UnidosFil: Mujic, Alija. University of Florida; Estados UnidosFil: Healy, Rosanne. University of Florida; Estados UnidosFil: Kuhar, José Francisco. Centro de Investigación y Extensión Forestal Andino Patagónico; ArgentinaFil: Furci, Giuliana. Fundacion Fungi; ChileFil: Torres, Daniela Soledad. Universidad Nacional de Río Cuarto. Facultad de Ciencias Exactas Fisicoquímicas y Naturales; ArgentinaFil: Niskanen, Tuula. Royal Botanic Gardens; Reino UnidoFil: Sandoval Leiva, Pablo A.. Museo Nacional de Historia Natural de Chile; ChileFil: Fernández, Natalia Verónica. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Patagonia Norte. Instituto de Investigaciones en Biodiversidad y Medioambiente. Universidad Nacional del Comahue. Centro Regional Universidad Bariloche. Instituto de Investigaciones en Biodiversidad y Medioambiente; ArgentinaFil: Escobar, Julio Martin. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Austral de Investigaciones Científicas; ArgentinaFil: Moretto, Alicia Susana. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Austral de Investigaciones Científicas; ArgentinaFil: Palfner, Götz. Universidad de Concepción; ChileFil: Pfister, Donald. Harvard University; Estados UnidosFil: Nouhra, Eduardo Ramon. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto Multidisciplinario de Biología Vegetal. Universidad Nacional de Córdoba. Facultad de Ciencias Exactas Físicas y Naturales. Instituto Multidisciplinario de Biología Vegetal; ArgentinaFil: Swenie, Rachel. University of Tennessee; Estados UnidosFil: Sanchez Garcıa, Marisol. University of Tennessee; Estados UnidosFil: Matheny, P. Brandon. University of Tennessee; Estados UnidosFil: Smith, Matthew. University of Florida; Estados Unido